- Home
- AUPH vs RBCAA Comparison
AUPH vs RBCAA Comparison
Compare AUPH & RBCAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- RBCAA
- Stock Information
- Founded
- AUPH 1993
- RBCAA 1974
- Country
- AUPH Canada
- RBCAA United States
- Employees
- AUPH 300
- RBCAA N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- RBCAA Major Banks
- Sector
- AUPH Health Care
- RBCAA Finance
- Exchange
- AUPH Nasdaq
- RBCAA Nasdaq
- Market Cap
- AUPH 1.2B
- RBCAA 1.3B
- IPO Year
- AUPH 1999
- RBCAA 1998
- Fundamental
- Price
- AUPH $8.93
- RBCAA $72.11
- Analyst Decision
- AUPH Strong Buy
- RBCAA Hold
- Analyst Count
- AUPH 2
- RBCAA 1
- Target Price
- AUPH $11.50
- RBCAA N/A
- AVG Volume (30 Days)
- AUPH 2.1M
- RBCAA 62.4K
- Earning Date
- AUPH 07-31-2025
- RBCAA 07-18-2025
- Dividend Yield
- AUPH N/A
- RBCAA 2.50%
- EPS Growth
- AUPH N/A
- RBCAA 27.68
- EPS
- AUPH 0.27
- RBCAA 6.28
- Revenue
- AUPH $247,295,000.00
- RBCAA $369,212,000.00
- Revenue This Year
- AUPH $12.15
- RBCAA $2.48
- Revenue Next Year
- AUPH $18.34
- RBCAA $2.11
- P/E Ratio
- AUPH $33.57
- RBCAA $11.48
- Revenue Growth
- AUPH 29.20
- RBCAA 16.32
- 52 Week Low
- AUPH $5.20
- RBCAA $54.88
- 52 Week High
- AUPH $10.67
- RBCAA $80.68
- Technical
- Relative Strength Index (RSI)
- AUPH 57.25
- RBCAA 44.64
- Support Level
- AUPH $8.73
- RBCAA $72.84
- Resistance Level
- AUPH $9.37
- RBCAA $77.94
- Average True Range (ATR)
- AUPH 0.41
- RBCAA 1.72
- MACD
- AUPH 0.04
- RBCAA -0.47
- Stochastic Oscillator
- AUPH 77.28
- RBCAA 15.14
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About RBCAA Republic Bancorp Inc.
Republic Bancorp Inc operates as a financial institution that provides both traditional and non-traditional banking products through five reportable segments. It has traditional banking which generates the majority of revenue, Warehouse Lending, Tax Refund Solutions (TRS), Republic Payment Solutions segment, and Republic Credit Solutions (RCS) business segments. The business activities of these segments include retail mortgage and commercial lending, construction and land development lending, internet lending, correspondent and indirect lending and also private banking, treasury management services, internet, and mobile banking, bank acquisitions, short-term revolving credit facilities, fixed-term residential real estate loans and receipt and payment of federal.